Esophageal Cancer
Conditions
Keywords
Esophageal Cancer, esophagectomy, enteral feeding, body composition, immunology
Brief summary
This study aims to examine whether providing tube feeding with a formula enriched with omega-3 fats is better than traditional standard tube feeding in terms of preserving nutritional status, improving immune function and reducing medical complications following major upper Gut cancer surgery.
Detailed description
Title A double blinded randomized controlled trial to investigate the effects of an enteral nutritional supplement enriched with Eicosapentaenoic acid on long term nutritional status post operatively specifically the maintenance of lean body mass, and its potential impact on quality of life as well as examining the stress response and immune function and in patients undergoing surgical treatment of esophageal cancer. Investigational medicinal Product(s): Prosure (Abbott Laboratories) Comparator: Ensure Plus (Abbott Laboratories) Study Objectives To examine whether prolonged supplementation with a nutritional supplement enriched with Eicosapentaenoic acid is superior to standard nutritional products in terms of promoting anabolism and improving quality of life in patients undergoing surgical treatment of esophageal cancer. Study Design - Prospective randomized controlled trial. Primary Endpoints: * Quality of life Scores using EORTC Questionnaires * Nutritional status on day 21 post oesophagectomy and/or total gastrectomy(specifically lean body mass) and at out patient follow up Secondary Endpoints: * Effects on the immuno-inflammatory response to surgery * Post operative Clinical outcome including SIRS, sepsis and organ failure
Interventions
DIETARY_SUPPLEMENTProsure
This is an enteral tube feed with 125 kcals & 6.65g protein per 100mls. It contains Fat, Carbohydrate, and vitamins and minerals and is enriched with 2.2g Eicosapentaenoic Acid per 500mls of feed. Patients on this trial who are randomized to Prosure will receive the product orally for 5 days prior to surgery and for 21 days post surgery vis a feeding jejunostomy tube
DIETARY_SUPPLEMENTEnsure Plus
This is a standard enteral tube feed with 150 kcals & 6.3 g protein per 100mls as well as carbohydrate, fat and vitamins and minerals. It does not have any active immunonutrients. Patients randomized to this arm will receive the product for 5 days pre op and 21 days post surgery via a feeding jejunostomy tube
Sponsors
Abbott
University of Dublin, Trinity College
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Adult (male & female) patients \>18 years with resectable esophageal cancer
Exclusion criteria
* Patients with metastatic disease, * Non-operable cases, * Patients requiring chemotherapy/radiotherapy early following surgery, * Patients with known immunological disorder, * Emergency esophagectomy cases, * Patients with cardiac, liver or renal failure, * Active small intestinal disease eg Crohns disease, * Allergy to any of the ingredients, * Uncontrollable Diabetes, * Use of medications known to affect eicosanoid metabolism in two weeks prior to trial, * Use of fish oil/n-3 fatty acids, * Drug Abuse, * Unable to take preparation for 5 days preoperatively, * Pregnant women, * Cessation of enteral feeding for longer than 3 consecutive days post operatively for medical/surgical reasons (e.g. Chyle leaks).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Preservation of body compostition after surgery | 2 months |
Secondary
| Measure | Time frame |
|---|---|
| Reduced immuno-inflammatory response to surgery | 2 months |
Countries
Ireland
Contacts
Primary ContactAoife Ryan, PhD
Backup ContactJohn V Reynolds, MD
Outcome results
None listed